Boston Scientific Corporation (NYSE:BSX) Shares Bought by Boston Partners

Boston Partners increased its stake in Boston Scientific Corporation (NYSE:BSX) by 4.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,260,545 shares of the medical equipment provider’s stock after buying an additional 333,409 shares during the period. Boston Partners owned about 0.60% of Boston Scientific Corporation worth $228,983,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC increased its stake in Boston Scientific Corporation by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock valued at $122,000 after buying an additional 487 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 338 shares during the last quarter. Guardian Life Insurance Co. of America increased its stake in Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 49 shares during the last quarter. Commerce Bank bought a new stake in Boston Scientific Corporation during the first quarter valued at $207,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in Boston Scientific Corporation during the first quarter valued at $215,000. 92.08% of the stock is owned by institutional investors.

Boston Scientific Corporation (BSX) opened at 26.26 on Friday. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $28.51. The firm has a market capitalization of $36.03 billion, a price-to-earnings ratio of 46.98 and a beta of 1.09. The firm’s 50-day moving average is $27.38 and its 200-day moving average is $26.02.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.27 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post $1.26 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.com-unik.info/2017/08/11/boston-scientific-corporation-nysebsx-shares-bought-by-boston-partners.html.

BSX has been the subject of several research analyst reports. TheStreet raised shares of Boston Scientific Corporation from a “c+” rating to a “b” rating in a research report on Tuesday, April 25th. Stifel Nicolaus boosted their target price on shares of Boston Scientific Corporation from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price (up previously from $29.00) on shares of Boston Scientific Corporation in a research report on Thursday, April 27th. BMO Capital Markets reissued a “buy” rating and issued a $30.00 target price on shares of Boston Scientific Corporation in a research report on Wednesday, June 21st. Finally, Zacks Investment Research raised shares of Boston Scientific Corporation from a “hold” rating to a “buy” rating and set a $31.00 target price for the company in a research report on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Boston Scientific Corporation has a consensus rating of “Buy” and a consensus target price of $30.06.

In other Boston Scientific Corporation news, EVP Michael P. Phalen sold 15,500 shares of the firm’s stock in a transaction dated Tuesday, May 30th. The shares were sold at an average price of $27.25, for a total value of $422,375.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Daniel J. Brennan sold 92,158 shares of the firm’s stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the completion of the sale, the chief financial officer now owns 235,421 shares of the company’s stock, valued at approximately $6,469,369.08. The disclosure for this sale can be found here. Insiders sold a total of 236,489 shares of company stock valued at $6,440,888 in the last 90 days. Corporate insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit